Holen Sie sich die Stockscreener-App
43.70
7.61%
3.09
Vorhandelsmarkt:
45.49
1.79
+4.10%
Schlusskurs vom Vortag:
$40.61
Offen:
$41.65
24-Stunden-Volumen:
444.78K
Relative Volume:
0.99
Marktkapitalisierung:
$2.83B
Einnahmen:
$87.56M
Nettoeinkommen (Verlust:
$-167.47M
KGV:
-18.68
EPS:
-2.34
Netto-Cashflow:
$-148.20M
1W Leistung:
+8.92%
1M Leistung:
+7.48%
6M Leistung:
+1.39%
1J Leistung:
+58.97%
1-Tages-Spanne:
$41.00
$44.03
1-Wochen-Bereich:
$40.20
$44.34
52-Wochen-Spanne:
$27.47
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
43.70 | 2.83B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Stephens Reaffirms Overweight Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN
Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN
How the (KYMR) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN
Kymera rises after presentation at the J.P. Morgan event - MSN
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com
Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat
Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa
Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks
Kymera reports progress in immunology drug trials - Investing.com India
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times
Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan
Analysts Set Expectations for KYMR FY2029 Earnings - Defense World
Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK
Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times
Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $53.88 Consensus Price Target from Brokerages - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88 - MarketBeat
Vir Biotechnology (NASDAQ:VIR) & Kymera Therapeutics (NASDAQ:KYMR) Financial Contrast - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Receives “Outperform” Rating from Leerink Partners - Defense World
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal - Yahoo Finance
Leerink Partners Reaffirms Outperform Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Trading (KYMR) With Integrated Risk Controls - Stock Traders Daily
Geode Capital Management LLC Sells 996 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform Recommendation - MSN
BTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - MSN
State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC - Defense World
(KYMR) Investment Analysis - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG Research - MarketBeat
Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets - Defense World
Kymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR) - Seeking Alpha
BMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Thrivent Financial for Lutherans Takes $313,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
The Manufacturers Life Insurance Company Has $6.07 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO sets Kymera Therapeutics target at $55, rates Market Perform By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest Position - MarketBeat
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):